摘要
目的探讨不同剂量恩度联合顺铂胸腔灌注治疗非小细胞肺癌恶性胸腔积液的临床效果。方法回顾性分析陕西省宝鸡市中心医院2012年2月~2017年1月收治的非小细胞肺癌恶性胸腔积液患者76例临床资料,依据治疗方式不同进行分组,治疗Ⅰ组36例和治疗Ⅱ组40例。观察两组患者治疗前后肺功能、血气分析、生活质量评分情况,观察两组患者近期疗效、毒性反应情况。结果治疗后,治疗Ⅰ组和治疗Ⅱ组第一秒用力呼气容积(FEV1)、FEV1占预计值的百分比(FEV1%Pred)、FEV1/用力肺活量(FVC)、氧分压(PaO_2)、躯体功能、心理功能、社会功能、共性症状评分均高于治疗前,二氧化碳分压(PaCO_2)低于治疗前,差异有统计学意义(P<0.05)。治疗Ⅱ组治疗后FEV1、FEV1%Pred、FEV1/FVC、PaO_2、躯体功能、心理功能、社会功能、共性症状评分均高于治疗Ⅰ组,PaCO_2低于治疗Ⅰ组,差异有统计学意义(P<0.05)。治疗Ⅱ组近期疗效缓解率高于治疗Ⅰ组,差异有统计学意义(P<0.05)。两组消化道症状、骨髓抑制、发热、胸痛、心脏毒性发生率比较,差异无统计学意义(P>0.05)。结论60 mg恩度联合顺铂胸腔灌注治疗非小细胞肺癌恶性胸腔积液患者的肺功能和生活质量恢复良好,疗效明显,值得临床推广应用。
Objective To explore clinical effect of malignant pleural effusion in non-small cell lung cancer treated with different doses of Recombinant Human Endostatin Injection and Cisplatin thoracic perfusion. Methods Clinical data of 76 patients with malignant pleural effusion in non-small cell lung cancer in Baoji Central Hospital of Shaanxi Province from February 2012 to January 2017 were retrospectively analyzed. All patients were divided into treatment group I （36 cases） and treatment group H （40 cases） according to different treatment methods. The lung function, blood gas analysis and quality of life scores were observed before and after treatment in both groups. The short-term efficacy and toxicity between two groups were observed. Results FEV1, FEVI%Pred, FEV~/FVC, PaO2, physical function, mental function, so- cial function, common symptoms scores of treatment group I and treatment group 11 after treatment were higher than before treatment, PaCO2 was lower than before treatment, the differences were statistically significant （P 〈 0.05）. FEV1, FEV1%Pred, FEV1/FVC, PaO2, physical function, mental function, social function, common symptoms scores of treat- ment group II after treatment were higher than those of treatment group I , PaCO2 was lower than treatment group I , the differences were statistically significant （P 〈 0.05）. The remission rate of short-term effect in treatment group II was higher than that in treatment group I , the difference was statistically significant （P 〈 0.05）. There were no signifi- cant differences in incidence rate of gastrointestinal symptoms, myelosuppression, fever, chest pain and cardiac toxicity between two groups （P 〉 0.05）. Conclusion Lung function and life quality of Recombinant Human Endostatin Injection （60 mg） and Cisplatin perfusion in the treatment of non-small cell lung cancer patients with malignant pleural effusion are well recovered. The effect is obvious, it is wor- thy of clinical promotion and application .
出处
《中国医药导报》
CAS
2017年第23期88-91,106,共5页
China Medical Herald
关键词
不同剂量
恩度
顺铂
胸腔灌注
非小细胞肺癌
恶性胸腔积液
Different doses
Recombinant Human Endostatin Injection
Cisplatin
Thoracic perfusion
Non-small cell lung cancer
Malignant pleural effusion
